ទំព័រដើម › មហារីក (គ្រប់ប្រភេទ) › ម៉ាសាឈូសេត › Boston
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីក (គ្រប់ប្រភេទ) នៅក្នុង Boston, MA
ការសិក្សាចំនួន 86 សម្រាប់ មហារីក (គ្រប់ប្រភេទ) កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Boston (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Distance-Based Exercise to Preserve Function and Prevent Disability
កំពុងជ្រើសរើស
- Dana-Farber Cancer Institute, Boston
A Study of ASP3082 in Adults With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
កំពុងជ្រើសរើសដំណាក់កាល 1
- Beth Israel Deaconess Medical Center - Research, Boston
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- PHN-012-001 Site, Boston
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
កំពុងជ្រើសរើសដំណាក់កាល 3
- Investigative Site, Boston
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Center ( Site 4013), Boston
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Dana Farber/Harvard Cancer Center, Boston
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
កំពុងជ្រើសរើស
- Massachusetts General Hospital, Boston
Pan Tumor Rollover Study
កំពុងជ្រើសរើសដំណាក់កាល 2
- Dana_Farber Cancer Institute (DFCI), Boston
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Beth Israel Deaconess Medical Center ( Site 0107), Boston
- Dana-Farber Cancer Institute ( Site 0105), Boston
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Dana-Farber Cancer Institute /ID# 279690, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Institute, Boston
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana-Farber Cancer Institute ( Site 3013), Boston
Statins to Prevent Cancer Associated Blood Clots
កំពុងជ្រើសរើសដំណាក់កាល 4
- Beth Isreal Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors
កំពុងជ្រើសរើស
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs
កំពុងជ្រើសរើស
- Dana-Farber Cancer Institute, Boston
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
កំពុងជ្រើសរើសដំណាក់កាល 2
- Dana Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
កំពុងជ្រើសរើសដំណាក់កាល 2
- Dana-Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana-Farber Cancer Institute /ID# 271846, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Research Site, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana-Farber Cancer Institute, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Boston Medical Center, Boston
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Dana Farber Cancer Institute, Boston
Lurbinectedin in FET-Fused Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana-Farber Cancer Institute, Boston
Prostate Active Surveillance Study
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital (MG), Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
BRIDGE-SIC Efficacy Trial
កំពុងជ្រើសរើស
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Abatacept in Immune Checkpoint Inhibitor Myocarditis
កំពុងជ្រើសរើសដំណាក់កាល 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Boston Medical Center, Boston
- និង 1 ទៀត
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1
- Beth Israel Deaconess Medical Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Dana-Farber Cancer Institute, Boston
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Dana-Farber Cancer Institute, Boston
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1ស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Boston Medical Center, Boston
- Massachusetts General Hospital (MGH), Charlestown · ឆ្ងាយ 1 ម៉ាយ
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
កំពុងជ្រើសរើសដំណាក់កាល 1
- Brigham and Women's Hospital, Boston
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
កំពុងជ្រើសរើសដំណាក់កាល 2
- Massachusetts General Hospital /ID# 273608, Boston
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Dana-Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
The STOP-MED CTRCD Trial
កំពុងជ្រើសរើសដំណាក់កាល 4
- Brigham and Women's Hospital, Boston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
កំពុងជ្រើសរើសដំណាក់កាល 1
- GSK Investigational Site, Boston
- GSK Investigational Site, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Childhood Cancer Survivor Study
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Dana-Farber Cancer Institute, Boston
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
កំពុងជ្រើសរើស
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site, Boston
- Research Site, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
Multisite Implementation of COMPRENDO
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Dana Farber Cancer Institute/Boston Children's Hospital, Boston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital,, Boston
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
កំពុងជ្រើសរើសដំណាក់កាល 1
- GSK Investigational Site, Boston
Video Inspired Discussions About Ethical Outcomes in Pediatrics
កំពុងជ្រើសរើស
- Dana Farber Cancer Institute, Boston
On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety
កំពុងជ្រើសរើសបញ្ជាក់ពីការបង់ប្រាក់សម្រាប់អ្នកចូលរួម
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
កំពុងជ្រើសរើសដំណាក់កាល 2
- Dana Farber Cancer Institute, Boston
Intraoperative Tumor Margin Identification With ICG Dye Imaging
កំពុងជ្រើសរើសដំណាក់កាល 2
- Massachusetts General Hospital, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Institute, Boston
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
Suprachoroidal Administration in Subjects With Metastases to the Choroid
កំពុងជ្រើសរើសដំណាក់កាល 2
- Massachusetts Eye and Ear, Boston
Supportive Care Intervention for Outpatient Stem Cell Transplant Patients
កំពុងជ្រើសរើស
- Dana-Farber Cancer Institute, Boston
Positron Emission Tomography (PET) Imaging of Thrombosis
កំពុងជ្រើសរើសដំណាក់កាល 1ស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Massachusetts General Hospital, Boston
Primary Tumor Research and Outcomes Network
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massachusetts General Hospital, Boston
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
កំពុងជ្រើសរើស
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
PediRISE Feasibility
កំពុងជ្រើសរើស
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Dana-Farber Cancer Institute /ID# 230061, Boston
A Dyadic Intervention for Young Adult Patients With Cancer and Their Partner Caregivers
កំពុងជ្រើសរើស
- Massachusetts General Hospital Cancer Center, Boston
A Study of YL242 in Subjects With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- US-204, Boston
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Boston Children's Hospital, Boston
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Codman Square Health Center, Boston
- East Boston Neighborhood Health Center, East Boston · ឆ្ងាយ 2 ម៉ាយ
Childhood Cancer Predisposition Study (CCPS)
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Dana Farber Cancer Institute, Boston
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
កំពុងជ្រើសរើស
- Massachusetts General Hospital Cancer Center, Boston
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massachusetts General Hospital, Boston
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
កំពុងជ្រើសរើស
- Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Massachusetts General Hospital, Boston
ការសាកល្បងសម្រាប់ មហារីក (គ្រប់ប្រភេទ) នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 121
- New York City, NYការសិក្សា 110
- Los Angeles, CAការសិក្សា 73
- Nashville, TNការសិក្សា 65
- Philadelphia, PAការសិក្សា 59
- Durham, NCការសិក្សា 58
- Washington, DCការសិក្សា 58
- Chicago, ILការសិក្សា 51
- Seattle, WAការសិក្សា 49
- Atlanta, GAការសិក្សា 49
- Arlington, VAការសិក្សា 48
- St. Louis, MOការសិក្សា 46
ការសិក្សាផ្សេងទៀតនៅក្នុង Boston
- មហារីកទ្រូងការសិក្សា 111
- Non-Small Cell Lung Cancerការសិក្សា 90
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 63
- មហារីកដែលរីករាលដាលការសិក្សា 63
- មហារីកសួតការសិក្សា 62
- មហារីកស៊ុតការសិក្សា 61
- មហារីកតូចការសិក្សា 59
- ភាពសោកសៅការសិក្សា 52
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 50
- បេះដូងខ្សោយការសិក្សា 44
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 44
- មហារីកតំបក់ការសិក្សា 43
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 5 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។